课题基金 / 基金详情

项目摘要

项目成果

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Project Summary / Abstract The overall goal for this Gateway Award is to evaluate B cell endotypes and examine how an endotype may be associated with T1D progression in autoantibody-positive individuals. Importantly, this award will provide an opportunity for the PI, as an Early Stage Investigator, to formally collaborate with Type 1 Diabetes TrialNet. The natural history of T1D is well understood, progressing from genetic risk, to autoimmunity, to clinical disease, and then to further ongoing loss of beta cell function. However, each step of this progression, as well as response to disease modifying immune therapy, is characterized by considerable heterogeneity. Much of our own work has aimed to identify immune markers that explain this heterogeneity; we recently showed that more rapid disease progression after diagnosis was evident in younger subjects with an increased B cell signature, and that this same signature predicted response to a B-cell targeting drug. Together, these findings suggest that B cells play an important role in some individuals with T1D. We propose that B cell characteristics may identify an endotype, or underlying disease mechanism of T1D that may be selectively targeted therapeutically, and that this can be seen in at-risk individuals as it was in the new onset setting. Despite these findings, there remain significant gaps in knowledge. First, can B cell endotypes observed after diagnosis explain heterogeneity in rate of progression from antibody positivity to clinical T1D? It is also unknown whether B cell endotypes are fixed characteristics of individuals or change as disease changes. Finally, it is likely that as-yet unidentified subpopulations of B cells, rather than the total population, mechanistically explain these findings. To address these gaps, we propose to address the hypothesis that B cell levels and signatures constitute a stable endotype prior to clinical diagnosis of T1D which will be associated with progression to T1D in the subset of subjects bearing this endotype.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
国内基金
海外基金
补阳还五汤通过AGE-RAGE通路调控脓毒症免疫失衡的机制与转化研究
靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
  • 批准号:
    JCZRQN202500010
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2025
  • 负责人:
  • 依托单位:
对香豆酸抑制AGE-RAGE-Ang-1通路改善海马血管生成障碍发挥抗阿尔兹海默病作用
  • 批准号:
    2025JJ70209
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2025
  • 负责人:
    雷芬芳
  • 依托单位:
AGE-RAGE通路调控慢性胰腺炎纤维化进程的作用及分子机制
  • 批准号:
    --
  • 项目类别:
    面上项目
  • 资助金额:
    --
  • 批准年份:
    2024
  • 负责人:
    万荣
  • 依托单位: